1. Scrip
  2. >>Therapy Areas
  3. >>Alimentary/Metabolic

Lilly To Deliver More Proof Points In Obesity, Keep Building Pipeline In 2024

Zepbound Readouts Expected In Co-Morbidities

 
• By Mandy Jackson

Research head Dan Skovronsky said it’s hard to improve upon tirzepatide, but Lilly is advancing early and late-stage obesity drugs while investigating internal and external assets in weight loss and beyond.

Lilly San Diego
Lilly will have readouts in obesity-related diseases for Zepbound in 2024 • Source: Shutterstock

Eli Lilly and Company’s obesity pipeline had a standout year in 2023 that will be hard to top in 2024, but the drug maker will continue delivering data to show the impact that significant weight loss with GLP-1/GIP agonist tirzepatide can have on related co-morbidities. And while the company awaits Phase III results from its next-generation obesity medicines retatrutide and orforglipron in 2025, it continues to scour the biopharmaceutical landscape for additional drug candidates.

Key Takeaways

  • Lilly will focus on its Zepbound launch and additional readouts for the obesity drug in 2024 while advancing its next-generation weight loss medicines.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Alimentary/Metabolic

Scholar Rock Shows Muscle-Building PoC In Obesity

 
• By Jessica Merrill

The company said it intends to maintain a focus on rare neuromuscular disease with apitegromab but could consider partnering in obesity.

Lilly Looks For Muscle-Sparing Candidates In Pact With Juvena

 
• By Joseph Haas

Deal Snapshot: Including its internal efforts with bimagrumab, Lilly has been seeking a muscle-sparing therapy to complement GLP-1 obesity drugs, such as Zepbound.

Novo Nordisk Teams With Deep Apple On Non-Incretin Obesity Approach

 
• By Joseph Haas

Novo Nordisk will partner with privately held Deep Apple to study a novel, non-incretin target that could be better suited than GLP-1s for long-term obesity treatment.

Metsera’s Amylin Analog Stars In Obesity Phase I

 
• By Joseph Haas

Intended as obesity monotherapy and for combination with the firm’s GLP-1 analog, MET-0233i showed best-in-class efficacy with placebo-like tolerability at low doses.

More from Conferences

Innovent Builds Metabolic Pipeline While Retaining Oncology Backbone

 
• By Xu Hu

Innovent presented data on multiple pipeline assets at ASCO, including promising OS results for its first-in-class anti-PD-1/IL-2α-bias bispecific. The Chinese firm is also continuing to build out its metabolic disease portfolio and consider its partnering strategies, its CEO tells Scrip.

BIO Notebook: IPO Window Stays Shut, PRVs Need To Be A Priority, And Focusing On Gene Therapy Safety

 
• By Mandy Jackson and Sarah Karlin-Smith

Highlights from day one of the BIO convention include advice for firms hoping to go public, a call for companies to push the US Congress on rare disease priority review vouchers, and updates on next-generation gene therapies.

Early Blood Cancer Data Impresses As Incyte Plots Post-Jakafi Strategy

 
• By Kevin Grogan

First results for a first-in-class mutCALR-targeted therapy in essential thrombocythemia presented at EHA point to a lucrative future for the early-stage product.